Board of Directors

Greg Lan

Non-Executive Director

Mr Lan joined the Probiotec board in February 2017. Mr Lan was the founding Managing Director of Sydney-based pharmaceutical company Aspen Pharmacare Australia, a subsidiary of South African listed Aspen Pharmacare Holdings. During Mr Lan’s tenure, Aspen Australia experienced exponential growth, particularly after the acquisition of Sigma’s branded and generics portfolio in 2011 (as well as its manufacturing facilities), and is today one of Australia’s largest pharmaceutical companies, with a diverse portfolio of over 260 products covering prescription and OTC. When Mr Lan retired after 15 years with the company, Aspen’s Asia Pacific operations (including Australia) had annualised sales in excess of $1 billion.

Prior to joining Aspen, Mr Lan has had extensive experience working in the pharmaceutical industry internationally, including senior roles with Ciba-Geigy (now Novartis) in Switzerland and Saudi Arabia, as well as with Sanofi-Aventis in Australia. Mr Lan holds an MBA from the University of Michigan.

Jonathan Wenig

Non-Executive Director, Chairman

Mr Wenig is currently a partner at Arnold Bloch Leibler, a leading Australian commercial law firm. Mr Wenig’s practice and expertise spans the breadth of commercial and corporate law, including mergers and acquisitions, corporate work, technology and financing. He is a trusted advisor to numerous active and innovative public companies – bringing his intellect and experience to bear not only in their corporate matters and acquisition activities, but across their legal affairs and strategic challenges and opportunities.
Mr Wenig is ranked as one of Australia’s leading Corporate and M&A lawyers in Chambers Asia Pacific and The Legal 500 Asia Pacific. He is also recognised by Best Lawyers® International in the area of corporate and M&A law and has been ranked by Doyle’s Guide in the categories of private equity and corporate law.

Wesley Stringer

Executive Director, Chief Executive Officer

Prior to joining Probiotec, Mr Stringer was employed by KPMG in Taxation and Finance. He has also worked internationally for Deutsche Bank and BNP Paribas Investment Bank in London.

Qualifications: B.Comm (Accounting, Finance), LLB (hons), CPA.

Simon Gray

Non-Executive Director

Mr Gray has a strong background in law, financial services and markets, risk and strategy. He was previously a director on the boards of Morgans Financial Limited and before that Shaw and Partners Limited where he was at various times its Deputy CEO, General Counsel and Chief Compliance Officer. Mr Gray is also Chair of the Australian Securities and Investments Commission’s Markets Disciplinary Panel and based in Sydney.